{"schema_version":"1","generated_at":"2026-10-28T02:29:18.220Z","data_as_of":"2026-10-25","url":"https://www.findmykol.com/kol/wenyin-shi","json_url":"https://www.findmykol.com/kol/wenyin-shi/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"wenyin-shi","name":"Wenyin Shi","credential":"MD","title":"Professor, Department of Radiation Oncology, Thomas Jefferson University; Medical Director of Radiation Oncology at Jefferson Hospital for Neuroscience (JHN)","specialty":"Radiation Oncology","specialty_raw":"Radiation Oncology","therapeutic_area":"Neuro-Oncology","therapeutic_areas":["Neuro-Oncology"],"institution":"Thomas Jefferson University","institution_url":"https://www.findmykol.com/institution/thomas-jefferson-university","city":"Philadelphia","state":"PA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1821178690","orcid":"0000-0002-6336-3912","openalex":"A5059909608"},"summary":"Wenyin Shi is Professor, Department of Radiation Oncology, Thomas Jefferson University; Medical Director of Radiation Oncology at Jefferson Hospital for Neuroscience (JHN) at Thomas Jefferson University. OpenAlex indexes 375 publications with 6,193 citations (h-index 35); ClinicalTrials.gov lists 13 registered studies with this person as an investigator.","overview":{"text":"Wenyin Shi, MD, PHD, is Professor, Department of Radiation Oncology, Thomas Jefferson University. The public record shows 375 publications with 6,193 citations (h-index 35), centered on Glioma Diagnosis and Treatment, Advanced Radiotherapy Techniques, Brain Metastases and Treatment. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 11 companies, 1 NIH-funded awards (2026–2026).","bullets":["Most recent indexed publication: 2026 · Journal of neuro-oncology","Top research focus: Glioma Diagnosis and Treatment","13 registered trials on ClinicalTrials.gov","Open Payments reporting from 11 companies"],"generated_at":"2026-10-27"},"focus":{"indications":[{"label":"Neuro-Oncology / Glioma","therapeutic_area":"Oncology","trials":5,"topics":1,"strength":16},{"label":"Glioma","therapeutic_area":"Oncology","trials":4,"topics":0,"strength":12},{"label":"Melanoma","therapeutic_area":"Oncology","trials":4,"topics":0,"strength":12},{"label":"Neoplasm Metastasis","therapeutic_area":"Oncology","trials":3,"topics":0,"strength":9},{"label":"Sarcoma","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Astrocytoma","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Gliosarcoma","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Oligodendroglioma","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Coma","therapeutic_area":"Neurology","trials":2,"topics":0,"strength":6},{"label":"Meningioma","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Brain Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Ependymoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Breast Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Lung Cancer (NSCLC/SCLC)","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Kidney Cancer / RCC","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Carcinoma, Small Cell","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Uveal Melanoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3}],"research_topics":["Glioma Diagnosis and Treatment","Advanced Radiotherapy Techniques","Brain Metastases and Treatment","Radiation Therapy and Dosimetry","Meningioma and schwannoma management"],"drugs_studied":{"total":2,"shown":2,"withheld":0,"rows":[{"name":"Eylea","generic":"Aflibercept","trials":0,"payments":1,"publications":0,"mentions":1},{"name":"Libtayo","generic":"Cemiplimab","trials":0,"payments":1,"publications":0,"mentions":1}]},"works_with":{"total":15,"shown":3,"withheld":12,"rows":[{"name":"Novocure Inc.","trials":0,"payments":46,"mentions":46},{"name":"Siemens Medical Solutions USA, Inc.","trials":0,"payments":22,"mentions":22},{"name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","trials":10,"payments":0,"mentions":10}]}},"scholarship":{"works_count":375,"cited_by_count":6193,"h_index":35,"i10_index":103,"pubmed_count":22,"latest_activity_year":2026,"source":"works"},"trials":{"count":13,"shown":3,"withheld":10,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT07353229","title":"68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma","phase":"PHASE1","status":"SUSPENDED","role":"Investigator","sponsor":"Thomas Jefferson University","source_url":"https://clinicaltrials.gov/study/NCT07353229","trial_url":"https://www.findmykol.com/trial/NCT07353229"},{"nct":"NCT06500455","title":"Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain","phase":"PHASE3","status":"RECRUITING","role":"Investigator","sponsor":"NRG Oncology","source_url":"https://clinicaltrials.gov/study/NCT06500455","trial_url":"https://www.findmykol.com/trial/NCT06500455"},{"nct":"NCT03712904","title":"Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma","phase":"PHASE2","status":"TERMINATED","role":"Investigator","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","source_url":"https://clinicaltrials.gov/study/NCT03712904","trial_url":"https://www.findmykol.com/trial/NCT03712904"}],"source":"trials"},"payments":{"company_count":11,"program_years":{"first":2021,"last":2025},"rows_total":20,"shown":3,"withheld":17,"rows":[{"payer":"Siemens Medical Solutions USA, Inc.","program_year":2025,"amount_usd":1692.45,"payment_count":12,"source_url":"https://openpaymentsdata.cms.gov/search?query=1821178690"},{"payer":"Novocure Inc.","program_year":2025,"amount_usd":1169.82,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1821178690"},{"payer":"Medtronic, Inc.","program_year":2025,"amount_usd":594.81,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1821178690"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1821178690","source":"payments"},"prescribing":{"data_year":2024,"areas_total":2,"areas_shown":2,"areas":[{"area":"Sensory organs","share_pct":77.8,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":77.8,"drugs":[{"name":"Dexamethasone","share_pct":100}],"max_beneficiaries":28}]},{"area":"Nervous system","share_pct":22.2,"classes_total":1,"classes":[{"class":"Benzodiazepine","setting":"prescribed","share_pct":22.2,"drugs":[{"name":"Lorazepam","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":3.1,"facility_pct":96.9},"source":"medicare"},"funding":{"award_count":1,"fiscal_years":{"first":2026,"last":2026},"rows_total":1,"shown":1,"withheld":0,"rows":[{"project":"UG1CA233341","title":"Sidney Kimmel Cancer Center LAPS Institutional Collaboration","fiscal_year":2026,"amount_usd":544790,"organization":"THOMAS JEFFERSON UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/UG1CA233341"}],"source":"grants"},"congress":{"count":70,"years":{"first":2007,"last":2026},"societies":["AACR","ASCO","ASTRO","ESMO"],"shown":3,"withheld":67,"rows":[{"title":"A phase II study of neoadjuvant cemiplimab in hedgehog inhibitor (HHI)–naive basal cell carcinoma of the head and neck.","society":"ASCO","meeting":"ASCO Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.9515","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.9515","status":"verified"},{"title":"Neoadjuvant cemiplimab in cutaneous basal cell carcinoma of the head and neck.","society":"ASCO","meeting":"ASCO Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2025.43.16_suppl.tps9606","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.tps9606","status":"verified"},{"title":"Multi-institutional study of reirradiation for recurrent high grade glioma.","society":"ASCO","meeting":"ASCO Annual Meeting","year":2024,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.2063","source_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.2063","status":"verified"}],"source":"congress"},"publications":{"total":22,"shown":5,"withheld":17,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"Feasibility evaluation of tumor treating fields for brainstem gliomas.","year":2026,"journal":"Journal of neuro-oncology","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42406140/","status":"verified"},{"title":"Modern molecular profiling recontextualizes the NRG/RTOG 0539 trial and reveals hidden high-risk and radiotherapy-resistant meningiomas.","year":2026,"journal":"Neuro-oncology","types":["Journal Article","Clinical Trial, Phase II"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42143623/","status":"verified"},{"title":"Metformin exposure after glioblastoma diagnosis and mortality: A large population-based study.","year":2026,"journal":"Neuro-oncology advances","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41788737/","status":"verified"},{"title":"Single-cell RNA sequencing suggests different progenitor lineages between IDH mutant and IDHwt glioma.","year":2026,"journal":"Neuro-oncology advances","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41727340/","status":"verified"},{"title":"Pituitary Macroadenoma and Adamantinomatous Craniopharyngioma: A Rare Case Report of Sellar Collision Tumors.","year":2025,"journal":"Case reports in neurological medicine","types":["Case Reports","Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/40949298/","status":"verified"}],"most_cited":{"total":375,"shown":5,"withheld":370,"rows":[{"title":"Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial","year":2014,"cited_by_count":1149,"type":"article","source_url":"https://doi.org/10.1200/jco.2014.57.2909"},{"title":"Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001","year":2020,"cited_by_count":850,"type":"article","source_url":"https://doi.org/10.1200/jco.19.02767"},{"title":"Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme","year":2014,"cited_by_count":225,"type":"article","source_url":"https://doi.org/10.1007/s11060-014-1362-0"},{"title":"Advanced magnetic resonance imaging in glioblastoma: a review","year":2017,"cited_by_count":213,"type":"article","source_url":"https://doi.org/10.21037/cco.2017.06.28"},{"title":"Multi-Institutional Dosimetric Evaluation of Modern Day Stereotactic Radiosurgery (SRS) Treatment Options for Multiple Brain Metastases","year":2019,"cited_by_count":128,"type":"article","source_url":"https://doi.org/10.3389/fonc.2019.00483"}]},"source":"publications"},"network":{"coauthors_total":40,"shown":3,"withheld":37,"coauthors":[{"name":"Maria Werner‐Wasik","coauthored_works":90,"profile_url":"https://www.findmykol.com/kol/maria-werner-wasik"},{"name":"David William Andrews","coauthored_works":83,"profile_url":"https://www.findmykol.com/kol/david-andrews-ca"},{"name":"Kevin D Judy","coauthored_works":70}],"source":"works"},"presence":{"owned_accounts":{"total":1,"shown":1,"rows":[{"platform":"doximity","url":"https://www.doximity.com/pub/wenyin-shi-md","status":"provisional"}]},"mentions":{"total":2,"shown":2,"rows":[{"url":"https://jefferson.edu/academics/colleges-schools-institutes/skmc/departments/radiation-oncology/faculty/directory/shi.html","platform":"other","status":"verified"},{"url":"https://profiles.jefferson.edu/display/32960","platform":"other","status":"verified"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":2,"shown":2,"rows":[{"value":"PhD, Pharmacology, University of Florida (2002)","source_url":"https://www.jefferson.edu/academics/colleges-schools-institutes/skmc/departments/radiation-oncology/faculty/directory/shi.html","status":"verified","collected_at":"2026-10-26"},{"value":"Shanghai Medical University, China (1997)","source_url":"https://www.jefferson.edu/academics/colleges-schools-institutes/skmc/departments/radiation-oncology/faculty/directory/shi.html","status":"verified","collected_at":"2026-10-26"}]},"roles":{"total":3,"shown":3,"rows":[{"value":"Guest Editor, Neuro-oncology focused issue, Chinese Clinical Oncology (2017), with Joshua D. Palmer","source_url":"https://cco.amegroups.org/issue/view/601","status":"verified","collected_at":"2026-10-26"},{"value":"Editorial Board Member, Chinese Clinical Oncology","source_url":"https://cco.amegroups.org/post/view/meeting-the-editorial-board-member-of-cco-dr-wenyin-shi","status":"verified","collected_at":"2026-10-26"},{"value":"Associate Editor, Radiation Oncology section, Frontiers in Oncology","source_url":"https://www.frontiersin.org/journals/oncology/sections/radiation-oncology/editors?page=11","status":"provisional","collected_at":"2026-10-26"}]},"awards":{"total":1,"shown":1,"rows":[{"value":"Castle Connolly Top Doctors (since 2015)","source_url":"https://cco.amegroups.org/post/view/meeting-the-editorial-board-member-of-cco-dr-wenyin-shi","status":"provisional","collected_at":"2026-10-26"}]},"secondary_affiliations":{"total":1,"shown":1,"rows":[{"value":"Department of Neurological Surgery, Thomas Jefferson University (professor)","source_url":"https://cco.amegroups.org/post/view/meeting-the-editorial-board-member-of-cco-dr-wenyin-shi","status":"provisional","collected_at":"2026-10-26"}]},"media":{"total":2,"shown":2,"rows":[{"value":"Chinese Clinical Oncology editorial board interview with Dr. Wenyin Shi (2024)","source_url":"https://cco.amegroups.org/post/view/meeting-the-editorial-board-member-of-cco-dr-wenyin-shi","status":"verified","collected_at":"2026-10-26"},{"value":"OncLive video: rationale to evaluate a tumor treating fields combination in glioblastoma (2021)","source_url":"https://www.onclive.com/view/dr-shi-on-the-rationale-to-evaluate-a-tumor-treating-fields-therapy-based-combination-in-glioblastoma","status":"provisional","collected_at":"2026-10-26"}]}},"similar":[{"name":"David Whellan","slug":"david-whellan","institution":"Thomas Jefferson University","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/david-whellan","json_url":"https://www.findmykol.com/kol/david-whellan/profile.json"},{"name":"Jesse Roman","slug":"jesse-roman","institution":"Thomas Jefferson University","specialty":"Pulmonary Disease","url":"https://www.findmykol.com/kol/jesse-roman","json_url":"https://www.findmykol.com/kol/jesse-roman/profile.json"},{"name":"Stephen Silberstein","slug":"stephen-silberstein","institution":"Thomas Jefferson University","specialty":"Neurology","url":"https://www.findmykol.com/kol/stephen-silberstein","json_url":"https://www.findmykol.com/kol/stephen-silberstein/profile.json"},{"name":"David Cognetti","slug":"david-cognetti","institution":"Thomas Jefferson University","specialty":"Otolaryngology","url":"https://www.findmykol.com/kol/david-cognetti","json_url":"https://www.findmykol.com/kol/david-cognetti/profile.json"},{"name":"Guy McKhann","slug":"guy-mckhann","institution":"Emory University School of Medicine","specialty":"Neurological Surgery","url":"https://www.findmykol.com/kol/guy-mckhann","json_url":"https://www.findmykol.com/kol/guy-mckhann/profile.json"},{"name":"Patrick Wen","slug":"patrick-wen","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/patrick-wen","json_url":"https://www.findmykol.com/kol/patrick-wen/profile.json"},{"name":"Minesh Mehta","slug":"minesh-mehta","institution":"Florida International University Herbert Wertheim College of Medicine","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/minesh-mehta","json_url":"https://www.findmykol.com/kol/minesh-mehta/profile.json"},{"name":"Timothy Cloughesy","slug":"timothy-cloughesy","institution":"Ronald Reagan UCLA Medical Center","specialty":"Neurology","url":"https://www.findmykol.com/kol/timothy-cloughesy","json_url":"https://www.findmykol.com/kol/timothy-cloughesy/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":10,"payments":17,"congress":67,"publications":17,"network":37}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-10-26"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-10-26"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2025","collected_at":"2026-10-26"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year","collected_at":"2026-10-26"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-10-26"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-10-26"}},"methodology_url":"https://www.findmykol.com/about#methodology"}